Ayres Lachlan Richard Owen, Clarke Shane, Digby-Bell Jonathan, Dhanda Ashwin Deep, Dharmasiri Suranga, Caddick Katharine, Collins Peter Lesley
Department of Liver Medicine, University Hospitals Bristol, Bristol, UK.
Rheumatology Department, University Hospitals Bristol, Bristol, UK.
Frontline Gastroenterol. 2012 Oct;3(4):220-227. doi: 10.1136/flgastro-2012-100186. Epub 2012 Jul 12.
Low bone mineral density (BMD) is common in chronic liver disease and predisposes to fracture. We aimed to compare British Society of Gastroenterology (BSG) and National Institute for Health and Clinical Excellence (NICE) osteoporosis guidelines with the fracture risk assessment tool (FRAX). FRAX is a web-based algorithm used to estimate fracture risk with or without dual-emission x-ray absorptiometry (DXA). Pre-BMD FRAX categorises patients to low, intermediate or high risk according to thresholds set by the National Osteoporosis Guidelines Group (NOGG) and recommends lifestyle advice, DXA or anti-osteoporosis treatment, respectively.
The guidelines were applied to 132 patients with cirrhosis (91% Child-Pugh A). The number that would require DXA and be recommended treatment was determined. Using post-BMD FRAX/NOGG as a reference point, high-risk patients not recommended treatment and low-risk patients treated 'unnecessarily' were identified.
BSG guidelines were applicable to 100% of the cohort, 88% required DXA and 30% would be recommended treatment. Equivalent figures for NICE guidelines were 30%, 17% and 12%, and for FRAX/NOGG guidelines were 78%, 27% and 15%, respectively. Using BSG guidance 8% of high-risk patients were not recommended treatment and 62% of those treated were low risk, compared with NICE: 3%, 60% and FRAX/NOGG: 13%, 40%, respectively.
For patients with Child-Pugh A cirrhosis BSG guidelines are the most inclusive, but have high cost implications in terms of DXA scanning and unnecessary treatment. Risk stratification using FRAX requires fewer DXA scans with minimal impact in terms of missing high-risk patients, and yields a modest reduction in unnecessary treatment.
低骨密度在慢性肝病中很常见,且易导致骨折。我们旨在比较英国胃肠病学会(BSG)和国家卫生与临床优化研究所(NICE)的骨质疏松症指南与骨折风险评估工具(FRAX)。FRAX是一种基于网络的算法,用于在有或没有双能X线吸收法(DXA)的情况下估计骨折风险。预骨密度FRAX根据国家骨质疏松症指南小组(NOGG)设定的阈值将患者分为低、中或高风险,并分别推荐生活方式建议、DXA或抗骨质疏松治疗。
将这些指南应用于132例肝硬化患者(91%为Child-Pugh A级)。确定需要进行DXA检查并被推荐治疗的患者数量。以骨密度测定后FRAX/NOGG为参考点,确定未被推荐治疗的高风险患者和“不必要”接受治疗的低风险患者。
BSG指南适用于100%的队列,88%的患者需要进行DXA检查,30%的患者将被推荐接受治疗。NICE指南的相应数字分别为30%、17%和12%,FRAX/NOGG指南的相应数字分别为78%、27%和15%。使用BSG指南时,8%的高风险患者未被推荐治疗,而接受治疗的患者中有62%为低风险,相比之下,NICE指南分别为3%、60%,FRAX/NOGG指南分别为13%、40%。
对于Child-Pugh A级肝硬化患者,BSG指南涵盖范围最广,但在DXA扫描和不必要治疗方面成本较高。使用FRAX进行风险分层所需的DXA扫描较少,遗漏高风险患者的影响最小,且不必要治疗略有减少。